Last reviewed · How we verify
gdT cell injection targeting B7-H3 chimeric antigen receptor
At a glance
| Generic name | gdT cell injection targeting B7-H3 chimeric antigen receptor |
|---|---|
| Also known as | UTAA06 injection |
| Sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors (PHASE1)
- Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: